Orocidin and Syngene Partner to Accelerate Biotech Innovation
Rhea-AI Summary
Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has announced a strategic partnership with Syngene International . The collaboration aims to advance GMP peptide development programs using cutting-edge technology and scalable solutions.
The partnership will focus on developing Orocidin's QR-01, leveraging Syngene's capabilities in efficient and scalable manufacturing with reduced lead times. Syngene's infrastructure will provide access to skilled scientists and state-of-the-art facilities, ensuring a robust and streamlined supply chain for future commercialization.
This strategic alliance aligns with Nordicus Partners' specialization in supporting Nordic and U.S. life sciences companies establishing themselves in the U.S. market.
Positive
- Strategic partnership secured with established peptide development company
- Access gained to advanced manufacturing capabilities and skilled scientists
- Potential for reduced lead times in product development
- Enhanced supply chain optimization for future commercialization
Negative
- None.
BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces a strategic partnership with Syngene International Limited (“Syngene”),
Syngene’s mission is to work as an extension of its client’s team. Together the teams solve the complex challenges associated with GMP peptide development programs using cutting-edge technology and scalable solutions, while maintaining the highest quality standards. Syngene’s capabilities enable efficient and scalable manufacturing with reduced lead times, ensuring the most robust and streamlined supply chain for future commercialization.
“We are very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time,” said Allan Wehnert, CEO & Founder of Orocidin. “This partnership secures access to highly skilled scientists and state-of-the-art facilities ensuring the development and progress of Orocidin’s QR-01.”
Alex Del Priore, Senior Vice President – Development & Manufacturing Services, Syngene International Ltd added: "We are delighted to partner with Orocidin in advancing their peptide programs. With a shared focus on speed, scale, and supply chain security, Syngene is well positioned to help biotech companies like Oricidin bring new drugs to market faster and more reliably.”
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Syngene
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.2 Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company’s latest Environmental, Social, and Governance (ESG) report, visit https://esgreport.syngeneintl.com.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What is the purpose of the Orocidin-Syngene partnership announced by NORD?
How will the Syngene partnership benefit NORD's subsidiary Orocidin?
What specific product is being developed through the NORD-Syngene collaboration?
How does the Syngene partnership align with NORD's business strategy?
